Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials

ConclusionsTopical, once ‐daily GT improved disease severity (ASDD/ASDD‐C, HDSS), sweat production, and quality of life (DLQI), with similar findings in children, adults, and the pooled population. GT was well tolerated, and treatment‐emergent adverse events were qualitatively similar between subgroups and consistent with other anticholinergics.

Source: Pediatric Dermatology - November 19, 2018 Category: Dermatology Authors: Adelaide A. Hebert, Dee Anna Glaser, Lawrence Green, William P. Werschler, Douglass W. Forsha, Janice Drew, Ramanan Gopalan, David M. Pariser Tags: ORIGINAL ARTICLE Source Type: research